These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31012561)

  • 1. Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy.
    Aljaser M; Amar L; Kircik LH
    J Drugs Dermatol; 2019 Apr; 18(4):336-340. PubMed ID: 31012561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
    Bagel J; Samad AS; Stolshek BS; Aras GA; Chung JB; Kricorian G; Kircik LH
    J Drugs Dermatol; 2018 Oct; 17(10):1078-1082. PubMed ID: 30365588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
    J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
    Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
    J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
    Bagel J; Nelson E; Riley C; Hetzel A
    J Drugs Dermatol; 2020 Dec; 19(12):1149-1155. PubMed ID: 33346509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
    J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
    Bagel J; Nelson E; Keegan BR
    J Drugs Dermatol; 2017 Oct; 16(10):957-962. PubMed ID: 29036248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Patient-Reported Outcomes With Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With Apremilast.
    Bagel J; Stolshek BS; Yang Y; Kricorian G; Kircik LH
    J Drugs Dermatol; 2020 Apr; 19(4):378-383. PubMed ID: 32272514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C; Cather J; Gooderham M; Poulin Y; Mrowietz U; Ferrandiz C; Crowley J; Hu C; Stevens RM; Shah K; Day RM; Girolomoni G; Gottlieb AB
    Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
    Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.
    Gottlieb AB; Strober B; Krueger JG; Rohane P; Zeldis JB; Hu CC; Kipnis C
    Curr Med Res Opin; 2008 May; 24(5):1529-38. PubMed ID: 18419879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
    Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y
    J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
    Radi G; Campanati A; Diotallevi F; Molinelli E; Offidani A
    G Ital Dermatol Venereol; 2019 Apr; 154(2):166-169. PubMed ID: 30229640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.
    Korman NJ; Warren RB; Bagel J; Armstrong AW; Gooderham M; Strober B; Thaçi D; Morita A; Imafuku S; Foley P; Sofen H; Zheng M; Hippeli L; Kisa RM; Banerjee S; Blauvelt A
    J Dermatolog Treat; 2024 Dec; 35(1):2371045. PubMed ID: 38945549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.